How Halotestin (Fluoxymesterone) Affects ALT

Fluoxymesterone (Halotestin) is a 17-alpha-alkylated oral steroid with very high androgenic activity and significant hepatotoxic potential:

1. C17-aa with halogenation: Halotestin is 17-alpha-alkylated and also 9-alpha-fluorinated. The fluorine substitution increases its metabolic stability and resistance to hepatic degradation, prolonging liver exposure.
2. Cholestatic and hepatocellular toxicity: Like other C17-aa steroids, halotestin impairs bile flow and causes direct hepatocyte damage. The severity is greater than Dianabol or stanozolol but comparable to or slightly less than superdrol.
3. Intense androgenic load: Halotestin has an androgenic rating approximately 19x that of testosterone. This extreme androgenic potency amplifies hepatic lipase activation and other androgen receptor-mediated hepatic effects.
4. Minimal anabolic-to-toxicity ratio: Halotestin provides relatively modest muscle-building effects compared to its toxicity, which is why it is used almost exclusively for short-term strength and aggression enhancement before competitions.

In bodybuilding, halotestin is a niche compound used primarily by powerlifters for competition day strength and by bodybuilders in the final 1-2 weeks of contest preparation for hardening effects. Extended use is universally discouraged due to its hepatotoxicity.

Low doses (10-20 mg/day):

• ALT typically rises 3-8x ULN (120-320 U/L)
• This range is common during brief pre-competition use
• Cholestatic markers (GGT, ALP) may be mildly elevated

Standard doses (20-40 mg/day):

• ALT commonly reaches 5-15x ULN (200-600+ U/L)
• AST rises proportionally
• Bilirubin elevation becomes likely at this dose range
• Mixed hepatocellular and cholestatic injury pattern

Timeline: Hepatotoxicity develops rapidly. Significant ALT elevation is typically evident within 7-14 days. Because halotestin cycles are usually only 2-4 weeks, the full course of hepatic injury is compressed into a short timeframe.

Recovery: After discontinuation, ALT typically returns to normal within 4-8 weeks. Longer cycles or higher doses may extend the recovery period.

Pre-cycle: Comprehensive liver panel. Do not use halotestin if baseline liver enzymes are elevated or if you have recently completed another oral steroid cycle.

On cycle: Check liver enzymes at day 10-14. Given the short typical cycle length (2-4 weeks), a single mid-cycle check may be all that is practical.

Post-cycle: Recheck at 2 weeks and 4-6 weeks post-discontinuation.

Cessation triggers:

• ALT exceeding 10x ULN
• Any bilirubin elevation
• Symptoms of cholestasis (itching, dark urine, pale stools)
• Right upper quadrant pain

Context-specific note: Many halotestin users take it only for the final 2 weeks before a competition. In this scenario, liver enzymes may peak after the competition, so post-competition bloodwork is important even if the user "feels fine."

Liver support:

• TUDCA 1000-1500 mg/day (essential)
• NAC 1200 mg/day
• Milk thistle 600-1000 mg/day
• Pre-load liver support 3-5 days before starting halotestin

Cycle design:

• Maximum 4 weeks; 2-3 weeks is the standard recommendation
• 10-20 mg/day is typically sufficient for strength and aggression effects
• Above 30 mg/day, hepatotoxicity escalates dramatically with diminishing additional benefit
• Never stack with another C17-aa oral steroid
• Allow 10-12 weeks of liver recovery before any subsequent oral steroid use

Pre-competition use:

• The most common protocol is 10-20 mg/day for the final 2 weeks before competition
• This short duration limits hepatic damage while providing the desired competition-day effects
• Liver support should continue for 2-4 weeks after the competition

Risk-benefit perspective: Halotestin has one of the worst hepatotoxicity-to-anabolic-benefit ratios of any oral steroid. It is not an effective mass-building drug. Its niche is limited to acute strength/aggression enhancement. Users should be clear about why they are using it and whether the benefits justify the liver risk.